Laura Martin | Authors


Reardon on ReACT: First Immunotherapy to Show Benefit in Glioblastoma

June 05, 2015

Targeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.

Jagannath Discusses Treatment Triplets, Immunotherapy for Myeloma

April 10, 2015

Novel combinations and immunotherapies have significantly expanded treatment options for myeloma. Numerous studies, including the ASPIRE and ELOQUENT-2 trials, have shown positive results for triple drug combinations.